Literature DB >> 8732596

Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis.

V G Valentine1, R C Robbins, G J Berry, H R Patel, H Reichenspurner, B A Reitz, J Theodore.   

Abstract

BACKGROUND: Obliterative bronchiolitis is a progressive form of obstructive airway disease that threatens long-term survival in lung transplant recipients. Its incidence and the long-term survival of lung transplant recipients with obliterative bronchiolitis are unknown.
METHODS: The results of 89 heart-lung and 13 bilateral sequential lung transplant survivors beyond 90 days of their operation were analyzed. The date of diagnosis for obliterative bronchiolitis was established histologically (presence of submucosal fibrosis) or physiologically by a persistent reduction in the forced vital capacity to less than 0.7 for greater than 6 weeks. There were 43 patients without obliterative bronchiolitis and 59 patients with obliterative bronchiolitis.
RESULTS: No differences were found in the mean age and gender ratios between the two groups. The actuarial 1-, 5-, and 10-year percentage freedom from obliterative bronchiolitis was 72 +/- 4.6, 30 +/- 5.6, and 15 +/- 7.4, respectively, with a median onset of 689 days (range 55 to 3404 days). About half the patients with biopsy-proven obliterative bronchiolitis had a fall in their forced expiratory flow at 50% of forced vital capacity/forced vital capacity nearly 4 months before fulfilling the forced expiratory volume in 1 second criteria established by the Working Group on chronic lung dysfunction. The actuarial 1-, 5-, and 10-year percentage survival of obliterative bronchiolitis negative patients was 90 +/- 4.5, 74 +/- 8.4, and 66 +/- 10.6, respectively, versus 90 +/- 3.9, 49 +/- 6.9, and 27 +/- 10.0, respectively, for obliterative bronchiolitis positive patients (p = 0.38). The actuarial 1-, 3-, 5-, 8-, and 10-year percentage survival of lung transplant recipients after the diagnosis of obliterative bronchiolitis was 74 +/- 5.8, 50 +/- 7.5, 43 +/- 7.8, 23 +/- 8.7, and 11 +/- 9.1, respectively, with a median survival of 1084 days (range 0 to 3442 days).
CONCLUSIONS: The forced expiratory flow at 50% of forced vital capacity/forced vital capacity is a more sensitive indicator for the early detection of obliterative bronchiolitis than the forced expiratory volume in 1 second after heart-lung or bilateral sequential lung transplantation. The obliterative bronchiolitis negative group survival tends to be better than the obliterative bronchiolitis positive group. The obliterative bronchiolitis positive lung transplant recipients have reasonable outcomes with a median survival time of nearly 3 years after the diagnosis of obliterative bronchiolitis. Earlier detection of obliterative bronchiolitis and refinements in management may further improve these results.

Entities:  

Mesh:

Year:  1996        PMID: 8732596

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  33 in total

1.  (3)He-MRI in follow-up of lung transplant recipients.

Authors:  Klaus Kurt Gast; Julia Zaporozhan; Sebastian Ley; Alexander Biedermann; Frank Knitz; Balthasar Eberle; Joerg Schmiedeskamp; Claus-Peter Heussel; Eckhard Mayer; Wolfgang Günter Schreiber; Manfred Thelen; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2003-10-16       Impact factor: 5.315

2.  Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.

Authors:  C Ashley Finlen Copeland; Laurie D Snyder; David W Zaas; W Jackson Turbyfill; W Austin Davis; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

Review 3.  Gastroesophageal reflux and altered motility in lung transplant rejection.

Authors:  J M Castor; R K Wood; A J Muir; S M Palmer; R A Shimpi
Journal:  Neurogastroenterol Motil       Date:  2010-05-26       Impact factor: 3.598

4.  Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.

Authors:  Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen
Journal:  J Heart Lung Transplant       Date:  2018-09-25       Impact factor: 10.247

Review 5.  A review of the potential applications and controversies of non-invasive testing for biomarkers of aspiration in the lung transplant population.

Authors:  C S Davis; J Gagermeier; D Dilling; C Alex; E Lowery; E J Kovacs; R B Love; P M Fisichella
Journal:  Clin Transplant       Date:  2010-03-19       Impact factor: 2.863

Review 6.  Molecular mechanisms of chronic rejection following transplantation.

Authors:  Elbert Kuo; Takahiro Maruyama; Felix Fernandez; T Mohanakumar
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Novel insights into lung transplant rejection by microarray analysis.

Authors:  Jeffrey D Lande; Jagadish Patil; Na Li; Todd R Berryman; Richard A King; Marshall I Hertz
Journal:  Proc Am Thorac Soc       Date:  2007-01

8.  Cross sectional study of exhaled nitric oxide levels following lung transplantation.

Authors:  A J Fisher; E Gabbay; T Small; S Doig; J H Dark; P A Corris
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

Review 9.  Overview of lung transplantation.

Authors:  Marlyn S Woo
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

10.  Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells.

Authors:  Aric L Gregson; Aki Hoji; Vyacheslav Palchevskiy; Scott Hu; S Samuel Weigt; Eileen Liao; Ariss Derhovanessian; Rajeev Saggar; Sophie Song; Robert Elashoff; Otto O Yang; John A Belperio
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.